| JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 卷:82 |
| Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials | |
| Article | |
| Gold, Linda Stein1  Del Rosso, James Q.2  Kircik, Leon3  Bhatia, Neal D.4  Hooper, Deirdre5  Nahm, Walter K.6  Stuart, Iain7  | |
| [1] Henry Ford Hlth Syst, Detroit, MI USA | |
| [2] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV USA | |
| [3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA | |
| [4] Therapeut Clin Res, San Diego, CA USA | |
| [5] Delricht Res, New Orleans, LA USA | |
| [6] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA | |
| [7] Foamix Pharmaceut Inc, Bridgewater, NJ USA | |
| 关键词: double-blind clinical trial; facial; minocycline; papulopustular rosacea; phase 3; topical foam; | |
| DOI : 10.1016/j.jaad.2020.01.043 | |
| 来源: Elsevier | |
PDF
|
|
【 摘 要 】
Background: Efficacious topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery. Objective: To determine the efficacy, safety, and tolerability of 12 weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea. Methods: Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea. Results: Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11: -17.57 vs -15.65; P =.0031; FX2016-12: -18.54 vs -14.88; P < .0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11: 52.1% vs 43.0%; P =.0273; FX2016-12: 49.1% vs 39.0%; P =.0077). No serious treatment-related treatment-emergent adverse events occurred. Limitations: The generalizability of these data from a controlled clinical trial should be examined in a real-world setting. Conclusions: FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile.
【 授权许可】
Free
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 10_1016_j_jaad_2020_01_043.pdf | 1176KB |
PDF